Third Rock Ventures and The Column Group have invested $25.1m in Series B capital in biotec startup Nurix, which is focused on developing therapies that modulate the ubiquitin proteasome system (UPS).
The round follows the company’s $6.2m seed financing round, which was led by the same investors in 2012.
The UPS directs protein degradation, a function vital to the healthy life of a cell, and could be used for the treatment of various diseases including oncology.
Third Rock partner and Nurix interim CEO Mark Goldsmith said, “Our understanding of the fundamental biology of the ubiquitin proteasome system and its role in select cancers and other diseases has grown significantly and continues to expand rapidly.
“These advances have enabled Nurix to make breakthrough biological, structural and chemical discoveries, positioning us to discover and develop small molecules with the potential to make a dramatic difference for patients.
“By combining a high-resolution molecular understanding of the ubiquitin proteasome system with innovative approaches to modulating its components, Nurix is making important progress in unlocking disease targets that have largely eluded drug discovery efforts.”
Earlier this year Third Rock participated in a $34m Series B for NinePoint Medical.
Copyright © 2014 AltAssets